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Folate and its synthetic form, folic acid (FA), are essential vitamins for the regeneration of S-adenosyl methionine molecules, thereby maintaining adequate
cellular methylation. The deregulation of DNA methylation is a contributing factor to carcinogenesis, as alterations in genetic methylation may contribute to stem
cell reprogramming and dedifferentiation processes that lead to a cancer stem cell (CSC) phenotype. Here, we investigate the potential effects of FA exposure on
DNA methylation and colonosphere formation in cultured human colorectal cancer (CRC) cell lines. We show for the first time that HCT116, LS174T, and SW480
cells grown without adequate FA demonstrate significantly impaired colonosphere forming ability with limited changes in CD133, CD166, and EpCAM surface
expression. These differences were accompanied by concomitant changes to DNA methyltransferase (DNMT) enzyme expression and DNA methylation levels,
which varied depending on cell line. Taken together, these results demonstrate an interaction between FA metabolism and CSC phenotype in vitro and help
elucidate a connection between supplemental FA intake and CRC development.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Folate; Colorectal cancer; Colonospheres; DNMT; Cancer stem cell; DNA methylation1. Introduction
Folate is the generic term for a group of essential B9 vitamin
compounds required for cellular biosynthesis and methylation [1].
Folic acid (FA) is the oxidized, more stable, synthetic form of folate
primarily found in supplements and fortiﬁed foods [1]. Naturally
occurring folate derivatives in their reduced forms are chemically
unstable, which contributes to nutrient loss during harvesting,
storage, and preparation [1,2]. Additionally, reduced folates require
separation from polyglutamyl chains prior to absorption at the brush
border, greatly reducing bioavailability [1–3]. In contrast, FA is
conjugated to only one glutamate residue and has close to 100%
bioavailability [1–3]. Once absorbed, FA must be converted to
dihydrofolate via dihydrofolate reductase in the liver before being
converted to tetrahydrofolatewhere it can enter the folate pool [1–3]. In
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,under tneural tube defects (NTD) subsequently led to the mandatory
fortiﬁcation of FA in grain products within Canada and the US [1,3].
Since then, a substantial beneﬁcial effect on the original target, NTD, has
been achieved but concerns have risen regarding the potential harmful
effects of such chronically high FA levels [1,3,4]. The high bioavailability
combined with its chemical stability has led to unnatural levels of
unmodiﬁed FA directly entering the circulation [1,3]. One of the
suggested risk factors associated with high FA intake is colorectal
cancer (CRC) [1,3,4]. Further research is required to deﬁne the complex
relationship between FA and CRC development to ensure safe and
responsible fortiﬁcation practices.
The role that B9 vitamin folate and its synthetic form, FA, play in
CRC development remains controversial [5–7]. Some epidemiological
studies report that high dietary and blood folate levels inhibit CRC
development [8,9]. However, more recent data from epidemiological
and clinical trial studies suggest that high FA intake and subsequent
high serum levels may actually increase cancer risk [10,11]. Rodent
studies suggest that the effect of FA on CRC development is dependent
on the underlying neoplastic status of the tissue [12]. FA supplemen-
tation before neoplastic transformation seems to be protective, while
that following the formation of potentially undetectable preneoplastic
colonic lesions may enhance CRC development [13]. Additionally, due
to the stability and high bioavailability of FA postfortiﬁcation, FA
exposure may have been underestimated, signiﬁcantly increasing FA
levels in the population. Therefore, fortiﬁcation of FA in Canada andhe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
819N. Farias et al. / Journal of Nutritional Biochemistry 26 (2015) 818–826the US may be inadvertently increasing the risk for CRC in
subpopulations vulnerable to colonic preneoplastic lesions.
The connection between folate and carcinogenesis is possibly a
result of its role in both nucleotide biosynthesis and DNAmethylation.
Folate deﬁciency has been shown to result in purine and thymidine
insufﬁciency, resulting in inadequate repair of DNA damage that
impairs cellular proliferation; this is the basis for antifolate chemo-
therapeutics [14–16]. Additionally, folate is critical for the provision of
methyl moieties that are used to synthesize S-adenosyl methionine
(SAM), the universal methyl donor for DNA methylation [17].
Methylation of cytosine-guanine dinucleotides (CpG) is an epigenetic
modiﬁcation essential in maintaining chromosomal stability and
regulating genetic expression in approximately half of all human
genes [17]. DNA methyltransferases (DNMTs) are the enzymes
responsible for establishing the original methylation pattern (de novo
methylases DNMT3a and DNMT3b) and for maintaining it throughout
subsequent cellular divisions (maintenance methylase DNMT1) [17].
Thus, FA plays a pivotal role in maintaining genomic integrity and gene
expression proﬁles.
AberrantDNAmethylation is a hallmark of cancer, including CRC, and
is characterized by both global hypomethylation [contributing to
oncogenic gene activation, loss of heterozygosity, and chromosomal
instability (CIN)] and simultaneous site-speciﬁc hypermethylation,
contributing to the inactivationof tumor suppressors [17–20]. Disrupting
DNA methylation patterns may allow cancer cells to manipulate gene
expression in order to repress differentiation while simultaneously
maintaining self-renewal, thus gaining a cancer stem cell (CSC)
phenotype [21,22]. CSCs share properties with native stem cells and
are vital in the development and perpetuation of tumor regrowth and
metastasis [23]. Somatic stem cells utilize the same mechanism to
maintain self-renewal as well as orchestrate cellular differentiation in a
timely and accurate manner [21]. Global hypomethylation is a common
and early event during CRC development [24], suggesting that it may be
associated with disrupted CSC reprogramming in the colon. Random
genomic hypomethylation alone may be sufﬁcient to deregulate
transcription factor activation, leading to ectopic gene expression and
increased CSC characteristics such as poor differentiation, increased
motility, and invasiveness [25,26]. Recent reports demonstrate that DNA
methylation regulates expression of colon CSC surface proteins aswell as
targets downstreamofWnt signaling [27,28], a vital pathway involved in
the maintenance of normal intestinal stem cells and the growth of CSC
in vitro [29].
Targeting the CSC population independently from the bulk of the
tumormay be an effective approach toward treating CRC [30]. The role
of FA in the maintenance of colorectal CSCs has yet to be determined
but may provide critical information on cancer development. In this
investigation, we studied the effects of FA exposure on global DNA
methylation and DNMT protein expression proﬁles in colon cancer
cells in vitro. These changes correlated with altered cell proliferation
under standardmonolayer conditions and altered the ability of cells in
nonadherent stem cell culture to generate colonospheres. Thus,
varying levels of FA supplementation can alter CRC cell proliferation,
DNA methylation, and stem cell phenotype in vitro.
2. Materials and Methods
2.1. Tissue culture
Human CRC cell lines HCT116, LS174T, and SW480 (purchased from the American
Type Culture Collection, Manassas, VA, USA) were cultured in Roswell Park Memorial
Institute 1640 media (RPMI-1640; Life Technologies, Burlington, ON, Canada),
containing 10% fetal bovine serum (FBS; Life Technologies) and 1% gentamycin
(Sigma-Aldrich, Oakville, ON, Canada) in a 37°C humidiﬁed incubatorwith 5% CO2. After
24 h, individual cultures were treated with folate-free RPMI-1640 (RPMI-1640, no FA;
Life Technologies) supplemented with 10% dialyzed FBS (DFBS; Life Technologies), 1%
gentamicin, and FA (Sigma-Aldrich) dissolved in 1 M NaOH. Treatment media
contained a ﬁnal concentration of 0 mg/L (deﬁcient), 4 mg/L (control), or 16 mg/L(excess) FA. Cells were resupplemented with media every 1–2 days, harvested after
7 days of treatment, and used for assays described below. The cell lines chosen for this
study represent various molecular pathways associated with colorectal carcinogenesis.
HCT116 and LS174T cells are both microsatellite instable (MSI), which refers to the
genomic instability that occurs in the cells particularly within repetitive regions [31].
MSI can occur due to a mutation resulting in nonfunctional mismatch repair machinery
or, more commonly, silencing of the machinery altogether as a result of promoter
methylation [32]. This results in the accumulation of unaddressed errors during DNA
replication. In addition, HCT116 cells show a CpG island methylator phenotype (CIMP)
characterized by epigenetic instability [31]. SW480 cells are characterized as
microsatellite stable (MSS)with a CIN phenotype [31]. Neoplasmswith CIN phenotypes
develop from the accumulation of structural and numerical chromosomal errors [32].
Genotypically, SW480 cells carry mutation in both p53 and adenomatous polyposis coli
(APC) while HCT116 and LS174T maintain the wild-type genes [31,33].2.2. Extraction and analysis of intracellular folates
Themethod of Kashani et al.was adopted for these analyses [34]. Treated cells were
trypsinized and washed three times with cold PBS. Cell pellets were resuspended in
0.05 M potassium phosphate buffer, pH 6.5, containing 0.2 M mercaptoethanol, and
stored at −80°C until analysis. For extraction of intracellular folates, cell suspensions
were boiled for 5 min then cooled at 4°C for 5 min. Resulting cell homogenates were
centrifuged at room temperature for 15 min at 1000g and supernatants were incubated
with 10% (by volume) charcoal-treated rat serum at 37°C for 2 h to convert folate
polyglutamate forms into monoglutamates. Protein was precipitated with 70%
methanol saturated with sodium ascorbate and the precipitates were removed by
centrifugation at 2000g at 4°C for 15 min. The samples were dried in ﬂowing nitrogen
gas at 37°C and kept on dry ice. Just before injection to high-performance liquid
chromatography (HPLC), the samples were resuspended in 0.25 ml of 0.05 M
potassium phosphate buffer, pH 6.5. The suspensions were ﬁltered through a 0.45-μm
membrane ﬁlter and 0.1 ml was injected into the reverse-phase column (SUPELCOSIL
LC-18, 25 cm×4.6 mm, 5 μm). HPLC was carried out using a Waters HPLC system
equipped with a HP Series 1050 UV detector set to 290 nm. The mobile phase was 10%
acetonitrile in 20 mMphosphate buffer, pH 3.3, pumped at aﬂow rate of 0.5 ml/min. FA
(MDL=0.03 mg/L), tetrahydrofolic acid (MDL=0.1 mg/L), and 5-methyltetrahydrofolic
acid (MDL=0.05 mg/L) were measured and expressed as values per 106 cells.2.3. Extraction and analysis of intracellular SAM and S-adenosyl homocysteine (SAH)
Analysis of SAMandSAHwasperformedbasedonapreviously publishedmethodwith
some modiﬁcations [35]. Treated cells were trypsinized and washed twice with cold PBS
and cell pellets were stored at −80°C until analysis. We added 1 ml cold 0.5 M HClO4
containing0.3%(w/v)Na2S2O5 and0.1%(w/v)EDTA to thecells on ice and soniﬁed for 15 s.
Sampleswere left on ice for 1 h to allowmacromolecules to precipitate, and samples were
centrifuged at 9000g for 15 min. The resultant supernatant was kept at −20°C until
analysis. Before analysis, pH was adjusted to 4–5 by NaOH. The samples were ﬁltered
througha0.45-μmmembraneﬁlter and0.1 mlwas injected into the reverse-phase column
(SUPELCOSIL LC-18, 25 cm×4.6 mm, 5 μm). The HPLC measurements were carried out
using a Waters HPLC system equipped with a HP Series 1050 UV detector set to 254 nm.
The mobile phase was 18% acetonitrile in 20 mM phosphate buffer, pH 4.5, and was
pumped at a ﬂow rate of 0.5 ml/min. SAM (MDL=1.0 mg/L) and SAH (MDL=1.0 mg/L)
were measured and expressed as values per 106 cells.2.4. Proliferation assays
Cell number and viability were measured using Trypan blue exclusion and methyl
thiazolyl tetrazolium (MTT) assay (both from Sigma-Aldrich). A total of 5×103 cells
were transferred to individual wells on a 96-well plate and treated with different
treatment media as described above. After 7 days, MTT assay was performed according
to manufacturer's directions. The absorbance of each well was then measured using a
96-well colorimetric plate reader at a test wavelength of 570 nm and reference
wavelength of 690 nm, and percent viability was calculated as (corrected optical
density of deﬁcient or excess FA-treated cells/corrected optical density of 4 mg/L
FA-treated cells)×100.2.5. Colonosphere limiting dilution analysis
Cells maintained under standard media conditions as described above were pelleted
at 350g for 4 min and resuspended in serum-free stem cell media (SCM) consisting of
Dulbecco's modiﬁed Eagle medium:nutrient mixture F12 (Life Technologies), 10% B27
supplement (Life Technologies), 10 ng/ml ﬁbroblast growth factor, 20 ng/ml epidermal
growth factor, and 1% gentamycin (all Sigma-Aldrich). Cell suspension was then plated in
96-well ultralow adhesion plates (Corning, Corning, NY, USA) at concentrations of 1, 10,
and 100 cells per well and cultured for 15 days with media changes every 3–4 days. The
number of colonosphere-positive wells was then counted to quantify the frequency of
sphere formation.
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After 7 days of incubation in FA-supplemented RPMI as described above, treated
cells were plated in 96-well ultralow adhesion plates (Corning) at 10 cells per well in
200 μl. Wells were resupplemented with media as described above. After 15 days, the
number of colonosphere-positive wells was then counted to quantify the frequency of
sphere formation.2.7. Western blotting
Cells treated with FA for 7 days were pelleted and disrupted with lysis buffer (Cell
Signaling Technology, Massachusetts, USA) containing protease inhibitors (Sigma-
Aldrich). Cell lysate was incubated for 5 min on ice before centrifugation at 12,000g for
15 min at 4°C. Supernatant was collected and the protein concentration was quantiﬁed
using theBio-RadDCProteinAssayKit.We loaded50 μgof totalprotein/sample into a7.5%
polyacrylamidegel and subject it to electrophoresis at 125 V for 80 min. Separatedprotein
was then transferred onto a methanol-activated polyvinylidene diﬂuoride membrane,
blocked for 1 h at room temperature with either 5% (w/v) nonfat milk or 5% BSA in
Tris-buffered saline/Tween 20 (TBS-T), and incubated overnight at 4°C with primary
antibodies diluted in 5% (w/v) nonfat milk or BSA. After incubation, membranes were
washedwith TBS-T, incubatedwith secondary antibodies in 5% (w/v) nonfatmilk in TBS-T
for 1 h at room temperature, washed, and subjected to chemiluminescent HRP substrate
Luminata Forte (Millipore, Darmstadt, Germany). Membranes were imaged using the
Bio-Rad ChemiDoc XRS+ system and densitometric analysis was performed using
the Image Lab Software (Bio-Rad). Molecular weight of proteins was determined by
comparison with GeneDirex BLUeye Prestained Protein Ladder (FroggaBio Inc.,
Toronto, ON, Canada). Densitometric analysis was done using the Bio-Rad Image Lab
Software. DNMT band density was normalized to α-tubulin band density for
semiquantitative analysis of protein levels. Primary antibodies included mouse-anti-
α-tubulin (1:600,000; Sigma-Aldrich), rabbit-anti-DNMT1 (1:2000; Cell Signaling),
rabbit-anti-DNMT3a (1:500; Cell Signaling), and rabbit-anti-DNMT3b (1:500; Cell
Signaling). Secondary antibodies included HRP-labeled goat-antimouse antibody
(1:20,000; Sigma-Aldrich) and HRP-labeled goat-antirabbit antibody (1:20,000;
Sigma-Aldrich).2.8. DNA isolation
Genomic DNAwas isolated from FA-treated cells using DNeasy Blood and Tissue Kit
(Qiagen, Venlo, Limburg, Netherlands) according to the manufacturer's protocol. The
concentration and purity were determined by measuring the absorbance at 230, 260,
and 280 nm using a Nanodrop ND-1000 (Thermo Scientiﬁc, Waltham, MA, USA).2.9. DNA methylation quantification
Global DNA methylation was quantiﬁed using EpiSeeker methylated DNA
Colorimetric Quantiﬁcation Kit (Abcam, Cambridge, UK) according to the manufac-
turer's directions, except that 300 ng of DNA per reaction was used. Absolute and
relative methyl-cytosine content was then calculated using the supplied formula.2.10. Flow cytometry analysis
CD133, CD166, and EpCAM staining was performed following FA treatment as
described above. Brieﬂy, cells were collected by trypsinization and ﬁxed in 4%
paraformaldehyde for 10 min at 37°C then chilled on ice for 1 min. Approximately 1×106
cells per treatment were blocked in 0.5% BSA/PBS for 10 min in room temperature then
incubated for 10–30 min at room temperature in PE-conjugated human-CD133 (Miltenyi
Biotec, San Diego, CA, USA), PerCP-conjugated human-EpCAM/TROP1 (R&D Systems, Inc.,
Minneapolis, MN, USA), and Alexa Fluor 488-conjugated human ALCAM/CD166
(R&D Systems, Inc.) antibodies diluted 1:22, 1:20, and 1:40, respectively, in 0.5% BSA/PBS.
Cells were collected and resuspended in PBS for analysis using a BD Accuri C6 ﬂow
cytometer (BD Biosciences, Mississauga, ON, Canada). Unstained cells were analyzed to
correct for background ﬂuorescence and to establish gating parameters for each cell line. In
total, 1×104 events were counted per sample.Fig. 1. FA levels inﬂuenced CRC cell proliferation in a dose-dependent and cell-line-
dependent fashion. (A) Relative proliferation of FA-treated cells quantiﬁed via MTT
assay, normalized to absorbance of 4 mg/L FA treatment. Percent viability was
calculated as (corrected optical density of deﬁcient or excess FA-treated cells/corrected
optical density of 4 mg/L FA-treated cells)×100. A total of 16 mg/L FA signiﬁcantly
increased proliferation of HCT116 and LS174T cells compared to the 0 mg/L FA
treatment (*P=.0127 and 0.0459, respectively). (B) Cellular proliferation quantiﬁed by
measuring viable cells via Trypan blue exclusion assay. A total of 16 mg/L FA in HCT116
and LS174T cells and 4 mg/L FA in SW480 cells signiﬁcantly increased proliferation
compared to the 0 mg/L FA (*P=.0407, 0.0136, and 0.0225, respectively). The data
represent the mean±S.E. of three independent experiments in triplicate.2.11. Statistical analysis
Statistical analysis was performed using GraphPad Prism software (GraphPad
Software Inc., La Jolla, CA, USA). Nonparametric Kruskal–Wallis and Dunn's multiple
comparison tests were used to determine if differences existed between treatments.
Linear regression was used to analyze changing intracellular FA levels in response to
medium supplementation. At least three biological replicates were used for each
statistical analysis, and treatments were considered signiﬁcantly different if statistical
tests produced a P value of ≤.05.3. Results
3.1. Cellular growth
HCT116 and LS174T cells treatedwith 16 mg/L FA had signiﬁcantly
increased cellular proliferation compared to 0 mg/L FA conditions
(P=.0127 and 0.0459, respectively; Fig. 1A). These results are in
agreement with results from Trypan blue exclusion experiments
showing that HCT116 and LS174T cells treated with 16 mg/L FA
had a signiﬁcantly higher number of viable cells compared to 0 mg/L
FA conditions (P=.0407 and 0.0136, respectively; Fig. 1B). Although
no signiﬁcant differences in the proliferation SW480 cells were
detected by theMTT assay (Fig. 1A), a signiﬁcant increase in viable cells
following 4 mg/L FA treatment compared to 0 mg/L FA was shown
(P=.0225; Fig. 1B).
3.2. Intracellular folate
Tomeasurewhether exposure to higher FA supplementation in cell
medium actively changed cellular folate levels, HPLC analysis was
done to quantify intracellular folate levels. HCT116, LS174T, and
SW480 cells all demonstrate a signiﬁcant positive correlation in
intracellular folate levels with increasing FA media supplementation
(P=.0023, P=.0459, and P=.0002, respectively; Fig. 2A–C). Despite
the lack of FA added to the 0 mg/L treatment group, these cells still
Fig. 2. Intracellular folate andmethionine compounds SAM and SAHweremeasured using HPLC. Linear regression of intracellular folate levels in response to FAmedia supplementation
in (A) HCT116 cells (P=.0023), (B) LS174T cells (P=.0459), and (C) SW480 cells (P=.0002). (D) Graph representing relative intracellular SAM:SAH ratios in response to FA treatment.
HCT116, LS174T, and SW480 cells all showed a signiﬁcant increase in SAM:SAH ratio in response to increasing FA (P=.0036, P=.00196, and P=.015, respectively). However, this effect
was mitigated following 16 mg/L FA in SW480 cells.
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72% less than the highest treatment group (16 mg/L FA). This may be
explained by the minute quantities of folate found in the DFBS
supplement added to the medium.
3.3. Intracellular SAM and SAH
To measure whether FA media supplementation had a physiolog-
ical consequence on methionine cycle intermediates, HPLC analysis
was done to quantify relative SAMand SAH levels. HCT116 and LS174T
cells both showed increasing SAM:SAH ratios with increasing FA
media levels, with the highest supplementation level (16 mg/L) being
60–50% greater than the corresponding lowest supplementation level
(0 mg/L) (P=.0036 and P=.00196, respectively; Fig. 2D). SW480 cells
showed a signiﬁcantly higher SAM:SAH ratio at the standard FA
supplementation level (4 mg/L FA) compared to the deﬁcient group
(0 mg/L) (P=.015); however, this effect was mitigated at the highest
supplementation level (16 mg/L) (Fig. 2D).
3.4. DNMT1, DNMT3a, and DNMT3b protein expression
Western blot analysis showed that increasing FA supplementation in
general resulted in increased DNMT1, decreased DNMT3a, and no
signiﬁcant effect on DNMT3b protein expression, with the exception of
SW480DNMT1protein expression. InHCT116 and LS174T cells, 16 mg/L
FA supplementation increased DNMT1 protein expression by 58–57%
(P=.0027 and P=.0048, respectively) and reduced SW480 cell DNMT1
protein expression by 60% (P=.0108) compared to 0 mg/L FA-treated
cells (Fig. 3A). HCT116 cells showed the only signiﬁcant change in
DNMT3a protein expression, with 85% reduction in the 16 mg/L FA-
supplemented group compared to 0 mg/L (P=.001; Fig. 3B). SW480 cells
also showed a suggestive, albeit nonsigniﬁcant, 50% reduction in
DNMT3a expression when supplemented with 16 mg/L FA compared
to 0 mg/L FA (Fig. 3B). DNMT3a proteinwas undetectable in LS174T cells
under all FA treatment levels (Fig. 3B). No signiﬁcant differences were
detected regarding changing DNMT3b protein levels; however, SW480cells showed a nonsigniﬁcant inverse dose response to FA level with a
64% reduction in DNMT3b protein level following 16 mg/L FA supple-
mentation compared to 0 mg/L FA (Fig. 3C). HCT116 cells also showed a
similar nonsigniﬁcant decrease inDNMT3aprotein level in the4 mg/L FA
group compared to 0 mg/L (Fig. 3C).
3.5. DNA methylation
We observed an inverse dose response between genomic DNA
methyl-cytosine content and FA supplementation (Fig. 4). The
methyl-cytosine content of DNA from HCT116 and LS174T cells was
46% and 57% higher, respectively, under 0 mg/L FA conditions
compared to cells treated with 16 mg/L FA (P=.0341 and P=.0341,
respectively) (Fig. 4). No signiﬁcant effects of FA treatment on global
DNA methyl cytosine were detected in SW480 cells.
3.6. Colonosphere formation
Monolayer cultured cells were passaged at concentrations of 1, 10,
and 100 cells per well in a 96-well ultralow adhesion plate (Corning)
supplementedwith SCM, to assess their ability to grow as colonospheres
(Fig. 5A). All cell lines showed a high ability to proliferate under these
conditions, and the efﬁciency of colonosphere formation signiﬁcantly
increased with number of cells originally plated (P≤.05; Fig. 5B). From
these data, it was determined that 10 cells per well was the optimal
number to assess differences in colonosphere formation in response to
FA treatment.
HCT116 cells treated with 0 mg/L FA signiﬁcantly produced 82.8%
and 84.4% fewer colonosphere-positive wells compared to cells treated
with 4 mg/L (P=.0411) and 16 mg/L (P=.0315) FA, respectively
(Fig. 6). LS174T cells treated with 0 mg/L FA produced 54.7% and
53.1% fewer colonosphere-positivewells compared to cells treatedwith
4 mg/L (P=.0087) and 16 mg/L (P=.0832) FA, respectively (Fig. 6). For
SW480 cells, however, 0 mg/L FA reduced colonosphere-positive wells
byonly 18%and14.8%compared to cells treatedwith 4 mg/L (P=.0448)
and 16 mg/L (P=.1646) FA, respectively (Fig. 6).
Fig. 3. Western blot analysis of DNMT protein expression in response to FA supplemen-
tation. Representativewestern blot and densitometric analysis of (A)DNMT1, (B)DNMT3a,
and (C) DNMT3b protein expression normalized to α-tubulin then to respective protein
expression in the 4 mg/L FA group. (A) A total of 16 mg/L FA signiﬁcantly increasedDNMT1
inHCT116 andLS174T cells and reduced it in SW480 cells (P=.0027,P=.0048, andP=.108,
respectively). (B) At total of 16 mg/L FA signiﬁcantly reduced DNMT3a protein expression
in HCT116 cells (P=.001). LS174T cell exhibited no detectable levels of DNMT3a protein in
all FA treatments. (C) No signiﬁcant differences were detected in DNMT3b protein
expression in response to FA treatment.
Fig. 4. FA supplementation reduced while FA deﬁciency increased global genomic
methyl-cytosine content. The percentage of 5-methyl cytosine (% 5mC) of each sample
was normalized to the 4 mg/L FA group for each cell line. A total of 16 mg/L of FA
signiﬁcantly reduced global methyl-cytosine content in HCT116 and LS174T cells
compared to the 0 mg/L FA conditions (*P=.0104 and P=.0434, respectively). The data
represent the mean±S.E. of three independent experiments in triplicate.
Fig. 5. Colonosphere formation of HCT116, LS174T, and SW480 cellswhen grown in SCM
under low-adhesion conditions. (A) Representative photomicrographs of HCT116,
SW480, and LS174T cells grown in monolayer (top) and in colonosphere culture for
10 days (bottom). Scale bar represents 100 μm. (B) Limiting dilution analysis of 1, 10,
and 100 cells per well. HCT116 cells plated at a density of 100 cells per well had
signiﬁcantly higher colonosphere yields than at 1 cell per well (*P=.0217), while
LS174T and SW480 cells plated at densities of both 10 and 100 cells per well had
signiﬁcantly higher colonosphere yields than at 1 cell per well (*P=.0233 and P=.0102,
respectively). The data represent the mean±S.E. of four independent experiments.
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Fig. 6. FA deﬁciency impairs colonosphere formation in HCT116, LS174T, and SW480
cells. HCT116 cells treated with either 4 mg/L FA or 16 mg/L FA generated signiﬁcantly
higher colonosphere yields than cells treated with 0 mg/L FA (*P=.0411 and P=.0315,
respectively). LS174T and SW480 cells treated with 4 mg/L FA generated signiﬁcantly
higher colonosphere yields than 0 mg/L FA-treated cells (*P=.0087 and P=.0448,
respectively). The data represent the mean±S.E. of four independent experiments.
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EpCAM, CD166, and CD133 surface proteins were expressed in all
CRC cell lines to varying degrees. HCT116 cells expressed high levels of
all surface markers (Fig. 7) on nearly 100% of cells despite changes in
FA exposure. CD133 and CD166 expression by SW480 and LS174T cells
was lower than that seen in HCT116 cells (Fig. 7A). LS174T cells show
trends toward reduced surface expression of all the markers with
increasing FA treatment; however, no signiﬁcant changes were
detected (PN.01; Fig. 7B and C). The proportion of SW480 cells with
positive CD133 expression decreased with increasing FA at 4 mg/L FA
and themedianCD133ﬂuorescence in these cellswashighest at 0 mg/L.
No other signiﬁcant changes were detected (Fig. 7B and C).
4. Discussion
We employed an in vitro model to investigate the association
between FA-induced changes in DNA methylation and CSC reprogram-
ming as revealed by CRC colonosphere formation and growth. Cells were
grown in media containing 0, 4, or 16 mg/L of FA for 7 days, after which
point they were passaged to suspension culture in serum-free media for
15 days. After 7 days, a signiﬁcant correlationbetweenFA supplemented
in themedia and intracellular FA levelswas observed in all cell lines. This
was accompanied by subsequent physiological changes in downstream
methionine cycle intermediates SAMand SAH. Theseﬁndings alongwith
the previous characterization of these in vitro functional folate levels
with transformed CRC cells support the suitability of these levels to
model isolated FA-dependent modulation [36–38].
FA deﬁciency signiﬁcantly reduced cellular proliferation in HCT116
and LS174T cells and survival in HCT116, LS174T, and SW480 cells. This
response is most likely attributed to compromised folate-dependent
genomic integrity, leading to cell cycle arrest and apoptosis. Folate
depletion has been shown to increase dUMP:dTMP ratios, which
increases uracil misincorporation during DNA synthesis [39]. Uracil
residues in close proximity on opposing strands can trigger double-
stranded breaks during DNA repair [40,41]. In response, DNA damage
signals the cell to inhibit cell cycle progression. Increased expression of
cell cycle modulating proteins p16, p21, and p15 has been reported in
FA-depleted colon epithelial cell lines [42]. Additionally, humanlymphocytes grown in folate-deﬁcient conditions show cell cycle arrest
in S-phase when uracil misincorporation occurs [43]. The difference in
proliferative abilities between HCT116 and LS174T, both p53 wild-type
cell lines, and SW480, a p53 mutant cell line, suggests that cell cycle
arrest following intracellular folate depletion may be p53 dependent.
However, consistent changes in viability between these cell lines
following folate depletion suggest that folate-deﬁciency-triggered cell
death occurs in a p53-independent manner.
To date, FA-dependent modulation of DNA methylation patterns
appears to be highly speciﬁc to the tissue, cell type, stage of
transformation, and even genetic locus [17,37,44,45]. Colon tissue
seems to be particularly resistant to folate-induced changes in genomic
methylation, a response that may be a result of robust SAM:SAH ratios
despite changes to methyl donor availability [46]. Sustained SAM:SAH
ratios during folate deﬁciency may be a result of up-regulated
compensatory mechanisms such as the selenium or choline/betain
pathways [36]. Alternatively, in response to FA deﬁciency, HCT116 has
been shown to up-regulate key mediators of the folate cycle,
particularly methylenetetrahydrofolate reductase (MTHFR), the en-
zyme responsible for converting 5,10-methylenetetrahydrofolate to
5-methyltetrahydrofolate [38]. As a result, HCT116 cells preferentially
shuttle folate pools to themethionine cycle over nucleotide biosynthesis
in anattempted tomaintain SAM-dependentmethylation reactions [38].
However, our data show that,while FA has a signiﬁcant dose-dependent
effect on SAM:SAH ratios, it also has an inverse dose effect on global
genomic methylation levels in HCT116 and LS174T CRC cells. This
suggests that FA-induced epigenetic changes in these cells are
associated with SAM- and SAH-independent pathways and that the
SAM:SAH ratio may not be a reliable biomarker for genomic
methylation. This hypothesis is supported by recent studies examining
more severe forms of folate deﬁciency in rats, which show that, while
such conditions reduce SAM:SAH ratios, paradoxically, an increase in
global methylation is observed in the colon [45]. Our results are also
consistentwithother studies showing that in vitro FAdeﬁciency can result
in both site-speciﬁc hypermethylation and global hypermethylation
[37,44]. A possible explanation for FA-, SAM-, and SAH-independent
effects onDNAmethylationmaybevia themodulationof themethylation
machinery [47].
The observed inconsistency between DNMT1 protein levels and
global DNA methylation suggests that reductions in DNMT1 alone may
not be sufﬁcient to induce signiﬁcant cellular hypomethylation in CRC
cells that already harbor global genomic hypomethylation. Although
DNMT1 is recognizedas theprimarymaintenancemethyltransferase, the
other DNMT isoformsmay be imperative for inducingde novo changes to
the DNA methylation code. One study has shown that, while complete
knockdown of DNMT1 in HCT116 cells resulted in a modest 20%
reduction in global genomic methylation, the complete knockdown of
both DNMT1 and DNMT3b in conjunction produced a N95% reduction in
global genomic methylation [48]. Indeed, our results show that, in
HCT116 cells, althoughFAdeﬁciency reducedDNMT1protein expression
by more than 50%, it also increased DNMT3a protein expression by 80%,
which may have mitigated any DNMT-dependent hypomethylation
effects, resulting in net global hypermethylation. However, the method
ofmethylation quantiﬁcation in this studywas limited to global analysis,
which is not sensitive enough to detect gene-speciﬁc differences. FA
levelsmodulateDNMTprotein expression, an effect that is highly speciﬁc
to both supplementation level and cell type. Previous work has shown
that both p53 andAPC status can act as regulatory factors in determining
DNMT1 expression [49,50]. This may explain why p53 and APC mutant
SW480 cells showedno signiﬁcant DNMT response to FA exposurewhile
HCT116 and LS174T do. However, in addition to altering DNMT protein
expression, previous studies have shown that FA levels also affect DNMT
enzyme activity and methyl CpG binding protein expression [47,51].
These results suggest that folate-dependent modulation of DNA
methylation may not solely be a result of altered SAM levels in the cell
Fig. 7. Fluorescence-activated cell sorting showing CD133, CD166, and EpCAMexpression in different CRC cells lines after 7 days FA treatment. (A) Representative ﬂowdiagrams for each
cell line. Shaded plot indicates signal for cells cultured with 4 mg/L FA and gray and black lines represent signal from cells cultured with 0 mg/L and 16 mg/L FA, respectively. (B and C)
Quantiﬁcation of CD133, CD166 and EpCAM staining frequency and intensity. HCT116 cells showed the highest level of expression and the greatest proportion of CD133 positive cells;
therewere no signiﬁcant effects on these parameterswith FA exposure. LS174T and SW480 cells showed lower levels of CD133, and SW480 cells showed a signiﬁcant reduction in CD133
positive cells in response to 4 mg/L FA treatment compared to 0 mg/L FA (*Pb.05). No other signiﬁcant effects were detected.
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downstream changes in DNA methylation may lead to aberrant genetic
activation, having consequences for cellular function, differentiation, and
survival [21,22].Unlike HCT116 and LS174T, SW480 cells showed no signiﬁcant
methylation effect in response to FA exposure. Themolecular pathway
characteristics of each cell type may indicate the type of colorectal
neoplasms that are vulnerable to FA-dependent epigenetic
825N. Farias et al. / Journal of Nutritional Biochemistry 26 (2015) 818–826modiﬁcations. As well as having a response to FA, HCT116 and LS174T
cells are both MSI positive cancers while SW480 cells are MSS [31]. In
addition, HCT116 cells also carry a CIMP phenotype and a known
mutation in the gene coding for MTHFR, reducing its effectiveness
[31,38]. Evidence suggests that folate status and MTHFR polymor-
phisms may be precursors associated with an increased risk of
developing MSI and CIMP-type neoplasms [52–54]. Therefore,
mutations to MTHFR or other folate cycle enzymes may leave cells
vulnerable to folate status-dependent aberrantmethylation leading to
MSI and CIMP phenotypes. Hence, it would be expected that CIMP and
MSI positive cancer cells such as HCT116 and LS174T have underlying
features predisposing them to aberrant methylation and therefore
may be more susceptible to FA-induced changes to genomic
methylation than MSI negative cancers such as SW480.
The hierarchical theory of tumor development stipulates that a
subpopulation of cells, termed CSCs or cancer progenitor/initiating
cells, are responsible for driving tumorigenesis [30]. A characteristic of
colorectal CSCs is their ability to grow into a ﬂoating multicellular
sphere from a single cell (termed a colonosphere) under anchorage-
independent conditions [29]. Here we show, for the ﬁrst time, that
deﬁcient FA exposure during monolayer culture signiﬁcantly reduced
the ability of CRC cells to form such colonospheres. To the best of our
knowledge, no other studies have shown that FA is required for
efﬁcient colonosphere formation.
Aside from altered intracellular FA levels, we found no consistent
physiological modiﬁcation in all cell lines that clearly alludes to
mechanisms governing FA's effect on colonosphere formation. Both
HCT116 and LS174T cells with elevated DNMT1 also had higher
colonosphere forming potential under increased FA conditions. This
has signiﬁcant implications for the role of FA in cancer therapy, as
manipulation of DNMT activity has shown promise as a therapeutic
strategy against CSC populations. Zebularine, a DNMT inhibitor,
selectively targets HCT116 cells with a CSC phenotype by reducing
the ALDH and CD44/CD166 positive cells in the culture and also has
a higher toxicity toward HCT116 colonospheres over monolayer
cells [55]. The complete knockdown of DNMT1 in SW480 and
HCT116 cells reduced expression of the CSC markers Sox and
CD133, reduced the cancer initiating frequency, and produced
xenograft tumors with reduced volume compared to DNMT1 wild-
type cells [56]. However, here, we show that the DNMT1 expression
proﬁle in FA-treated SW480 cells was opposite to that of HCT116
and LS174T cells despite maintaining consistent colonosphere
forming potential. This suggests that, while DNMT1 may contribute
to the physiological changes necessary for colonosphere formation,
it is not absolutely necessary.
The inﬂuence that the DNMT proteins have on CSC phenotype may
be a result of their modiﬁcations to DNA methylation and the
subsequent changes in genetic expression. Our data show that global
methylation changes andcolonosphere forming abilitywere concordant
in two out of the three cell lines, SW480 cells being the exception.
However, this does not rule out the possibility that potentially
undetectable, site-speciﬁc differences took place in all FA-supplemented
cells that may have enhanced colonosphere forming potential. Current-
ly, the only other studies that have investigated FA-dependent stem cell
proliferation involve neural stem cells. Yu et al. showed that FA
promotesmethylation changes in genes for key PI3K/Akt/CREB pathway
proteins, which subsequently led to stimulated neural stem cell
proliferation [57]. HCT116 and LS174T cells both harbor hyperactivating
mutations in PI3K while SW480 cells maintain the wild-type gene [31].
Differences in PI3K activitymay facilitate or exaggerate the effects of FA-
dependent stem cell proliferation as seen by the greater response of
HCT116 and LS174T cells compared to SW480 cells [31]. In another
study, FA was shown to increase Notch signaling leading to increased
neural stem cell proliferation [58]. The Notch signaling pathway along
with Wnt, Hedgehog, and TGF-β signaling pathways are involved inmaintaining normal colon stem cell renewal and have been implicated
in CRC CSC development [59]. This is important when considering that
SW480 cells carry amutation in the APC gene, which functions as aWnt
protooncogene [33]. This results in a loss of β-catenin regulation and a
constitutively active Wnt pathway [33]. Unregulated Wnt signaling
may be a contributing factor to the relative high levels of stem cell
proliferation despite differential FA exposure in SW480 cells [33].
Nevertheless, many of the key proteins involved in stem cell renewal
pathways are epigenetically regulated [27,60–62]. Thus, deregulated
protein transcription leading to the activation of stem cell pathways as a
result of FA-induced methylation changes may facilitate stem cell
reprogramming and colonosphere forming ability in these CRC cell lines.
Colonospheres from CRC cell lines have increased expression of
putative CRC stem cell markers such as CD133, CD166, CD144, CD24,
CD29, LGR5, and nuclear β-catenin as well as up-regulation of CSC
associated pathways compared to their monolayer derived equiva-
lents, which include theWnt, Notch, and Hedgehog pathways [29,63].
Although we saw changes in CD133 expression with FA, the results
were not concordant with colonosphere forming ability. For instance,
CD133 was highly expressed on virtually all HCT116 cells and did not
alter with FA exposure, yet there was a profound FA-dependent
difference in the ability of HCT116 cells to generate colonospheres.
Conversely, SW480 and LS174T cells showed overall low levels of
CD133 expression despite highly efﬁcient colonosphere forming
ability. LS174T cells also exhibited a slight reduction in CD166 and
EpCAM surface expression with increasing FA levels; however,
these results did not reach signiﬁcance. Taken together, these
ﬁndings suggest that although EpCAM, CD166, and CD133 are used
as “biomarkers” for CSCs in many types of cancer, including CRC
[64], their utility as indicators of colonosphere forming ability
(arguably a more relevant bioassay for CSCs) in cultured cell lines is
questionable [65].
In summary, the association among DNMT expression, FA
exposure, and CRC colonosphere growth outlined in this report
provides a possible mechanism by which FA can modulate CRC
development. Our data suggest that excessive FA intake from
supplements and fortiﬁed foods over a prolonged period of time
may contribute to aberrantmethylation patterns. This could provide a
survival advantage to preexisting colon neoplasms, perhaps as a
consequence of both DNMT protein modulation and altered methyl
donor availability in the cell. This association between FA intake,
methylation, and DNMT levels in cancer cells is an important step in
characterizing a potentially problematic relationship between nutrient
oversupplementation and cancer progression. We believe that these
effects pose signiﬁcant implications for in vitro and in vivo CSC models,
and future investigations are warranted.
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